期刊
BLOOD
卷 123, 期 14, 页码 2157-2160出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-11-536557
关键词
-
类别
资金
- Associazione Italiana per la Ricerca sul Cancro [1005]
- Ministero della Universita e Ricerca (MIUR) [RBAP11CZLK, PRIN 2010NYKNS7]
- Fondazione Cassa di Risparmio di Carpi
- AIL Modena ONLUS
- Novartis Pharma AG
The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-II). We performed a comprehensive mutation analysis to evaluate the impact of 14 MF-associated mutations on clinical outcomes in 166 patients included in COMFORT-II. We found that responses in splenomegaly and symptoms, as well as the risk of developing ruxolitinib-associated anemia and thrombocytopenia, occurred at similar frequencies across different mutation profiles. Ruxolitinib improved survival independent of mutation profile and reduced the risk of death in patients harboring a set of prognostically detrimental mutations (ASXL1, EZH2, SRSF2, IDH1/2) with an hazard ratio of 0.57 (95% confidence interval: 0.30-1.08) vs best available therapy. These data indicate that clinical efficacy and survival improvement may occur across different molecular subsets of patients with MF treated with ruxolitinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据